Get the Stockscreener App
43.67
0.88%
0.38
After Hours:
43.67
Livanova Plc stock is traded at $43.67, with a volume of 411.20K.
It is up +0.88% in the last 24 hours and down -4.80% over the past month.
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
See More
Previous Close:
$43.29
Open:
$43.55
24h Volume:
411.20K
Relative Volume:
0.59
Market Cap:
$2.38B
Revenue:
$1.28B
Net Income/Loss:
$-222.15M
P/E Ratio:
-10.68
EPS:
-4.09
Net Cash Flow:
$145.52M
1W Performance:
+4.03%
1M Performance:
-4.80%
6M Performance:
-9.30%
1Y Performance:
-18.30%
1-Day Range:
$42.85
$43.95
1-Week Range:
$41.98
$44.20
52-Week Range:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
Name
Livanova Plc
Sector
Industry
Phone
4402033250662
Address
20 EASTBOURNE TERRACE, LONDON
Compare LIVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
43.67 | 2.36B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Feb-26-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-04-24 | Initiated | Goldman | Buy |
| Sep-17-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-20-24 | Reiterated | Needham | Buy |
| Feb-20-24 | Upgrade | Mizuho | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Feb-24-22 | Upgrade | UBS | Neutral → Buy |
| Dec-03-21 | Initiated | Goldman | Buy |
| Aug-20-21 | Reiterated | Needham | Buy |
| Jul-20-21 | Upgrade | Needham | Hold → Buy |
| Mar-03-21 | Downgrade | Berenberg | Buy → Hold |
| Jan-05-21 | Downgrade | Needham | Buy → Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-26-20 | Reiterated | Needham | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-08-18 | Initiated | Stifel | Buy |
| May-31-18 | Reiterated | Needham | Buy |
| Feb-28-18 | Reiterated | Needham | Buy |
View All
Livanova Plc Stock (LIVN) Latest News
LivaNova’s VNS Therapy Shows Sustained Effectiveness in Drug-Resistant Epilepsy - Insider Monkey
Will LivaNova PLC stock benefit from interest rate changesFree Risk Assessment Services - jammulinksnews.com
What analysts say about LivaNova PLC stockMarket-leading capital gains - Autocar Professional
How CPBI stock compares to its top competitorsIs LivaNova PLC stock undervalued or overvalued nowFree Investment Portfolio Suggestions - jammulinksnews.com
Is LivaNova PLC a good long term investmentHigh-impact stock picks - jammulinksnews.com
External Pacemakers Market Set to Witness Significant Growth - openPR.com
What drives LivaNova PLC stock priceBreakthrough financial growth - Autocar Professional
LivaNova PLC Stock Analysis and ForecastAccelerated wealth expansion - Autocar Professional
Cardiac Autonomic Control Market Growth in Future Scope - openPR.com
In-Line Blood Monitoring Devices Market is projected to grow - openPR.com
Wearable Cardioverter Defibrillators Market is projected - openPR.com
Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT - MSN
Neuro Modulation Devices Market is expected to reach US$ 7.6 - openPR.com
(LIVN) Technical Data - news.stocktradersdaily.com
‘A vicious life loop’: Epilepsy community calls for action to address the burden of disease - medianet.com.au
Principal Financial Group Inc. Purchases 3,668 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
How LivaNova PLC stock performs during market volatilityStable Stocks With High Yield - Newser
Why LivaNova PLC stock attracts strong analyst attentionInsider Strategy Insight - Newser
Vagus Nerve Stimulators Market Exclusive Report with Detailed - openPR.com
LivaNova to Announce Second-Quarter 2025 Results | LIVN Stock Ne - GuruFocus
LivaNova to Announce Second-Quarter 2025 Results - Business Wire
LivaNova: The Sell-Off Is Excessive Here (NASDAQ:LIVN) - Seeking Alpha
Here's Why LivaNova (NASDAQ:LIVN) Can Manage Its Debt Responsibly - 富途牛牛
LivaNova PLC (LIVN): A High-Conviction Buy at Oversold Levels - AInvest
Livanova Plc Stock (LIVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):